Roche is buying Poseida Therapeutics for about $1.5 billion. The deal values Poseida stock at a massive premium.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback